New York, NY -- (SBWIRE) -- 12/26/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Cirrus Logic, Inc (NASDAQ:CRUS), Linn Energy LLC (NASDAQ:LINE), ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), ARRIS Group, Inc (NASDAQ:ARRS)
Cirrus Logic, Inc (NASDAQ:CRUS) showed a volume of 958,679.00 shares by the end of last trade whereas the average volume of the stock remained 2.49 million shares. The stock opened the session at $20.91 but then moved to $20.86. At that price, the stock showed a positive performance of 0.19%. Cirrus Logic, Inc. (Cirrus Logic) develops analog and mixed-signal integrated circuits (IC) for a broad range of consumer and industrial markets. Building on its diverse analog mixed-signal patent portfolio, Cirrus Logic delivers optimized products for consumer and professional audio, automotive entertainment, and targeted industrial applications, including energy control, energy measurement, light emitting diode (LED) lighting and energy exploration. The Company serves customers in the United States, Europe and Asia, including the People’s Republic of China, Hong Kong, South Korea,
Will CRUS Continue To Move Higher? Find Out Here
Linn Energy LLC (NASDAQ:LINE) opened the session at $30.19 and closed the session at $30.13. The stock showed a negative performance of -0.53% in previous trading session. Traded with volume of 931,030.00 shares in the prior session and the average volume of the stock remained 1.83 million shares. Linn Energy, LLC (LINN Energy) is an independent oil and natural gas company. The Company is engaged in acquiring, developing and maximizing cash flow from a growing portfolio of long-life oil and natural gas assets. The Company's properties are located in the United States , in the Mid-Continent, the Hugoton Basin, the Green River Basin, the Permian Basin, Michigan, Illinois, the Williston/Powder River Basin, California and east Texas. Proved reserves at December 31, 2012, were 4,796 billions of cubic feet equivalent,
Has LINE Found The Bottom And Ready To Gain Momentum? Find Out Here
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) opened the session at $26.13 and closed the session at $26.31. The stock showed a positive performance of 1.50% in previous trading session. Traded with volume of 929,499.00 shares in the prior session and the average volume of the stock remained 1.32 million shares. The beta of the stock remained 2.67. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma,
Why Should Investors Buy ACAD After The Recent Gain? Just Go Here and Find Out
ARRIS Group, Inc (NASDAQ:ARRS) the stock decreased -0.13% and finished the session at $23.49. Traded with volume of 904,169.00 shares in the prior session and the average volume of the stock remained 2.17 million shares. The beta of the stock remained 1.39.
Will ARRS Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)